Pixxoscan is intended for contrast enhancement in cranial and spinal MRI. Credit: Business Wire / GE HealthCare.

GE HealthCare has expanded its magnetic resonance imaging (MRI) contrast agent portfolio with the launch of Pixxoscan (gadobutrol).

Designed to enable the visualisation of abnormal structures or lesions, the new MRI agent helps differentiate between healthy and pathological tissue.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pixxoscan is intended for contrast enhancement in cranial and spinal MRI as well as magnetic resonance angiography.

It is suitable for individuals across all age groups including adults, adolescents and children (including term neonates).

Pixxoscan is also recommended for whole-body imaging in individuals suspected to have focal lesions to determine whether they are benign or malignant.

GE HealthCare pharmaceutical diagnostics chief medical officer Mark Hibberd said: “This extension to our portfolio means we will be able to offer two leading macrocyclic molecules – Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) – to our customers in a number of European countries, offering radiology departments even more choice to suit their diagnostic needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pixxoscan was assessed through a regulatory decentralised procedure (DCP) and already obtained marketing authorisation in Austria. DCP is a process to gain marketing authorisation in more than one European Union member state.

The company is currently awaiting approval for Pixxoscan and plans to introduce it in several European countries this year.

The company’s MRI contrast media portfolio also includes macrocyclic Clariscan (gadoteric acid) and Rapiscan.

Rapiscan is used in stress cardiac MR examinations to help diagnose coronary artery disease. For patients who are unable to exercise, it serves as a viable alternative used to simulate the same effect.